Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout The Company previously reported that higher single doses of PRX–115 lowered mean plasma uric acid for longer durations in participants with elevated plasma uric acid levels (ACR 2024) New individual patient data presented at ACR 2026 reinforce this finding and show the effect associated with PRX-115 plasma levels remaining measurable for up to 85 days The Company believes PRX-115 has best-in-class potential in uncontrolled gout, a high unmet need with top-line results from the Phase 2 RELEASE study expected in the second half of 2027 CARMIEL, Israel, Nov. 9, 2026 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the discovery, development, production, and commercialization of innovative therapeutics... Read more





US
IE
IN
AU
JP
BM
CA